Table 3. Factors associated with a ≥8-week delay to adjuvant chemotherapy (n = 597).
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| ≥8 weeks | <8 weeks | P | HR (95%CI) | P | ||
| N (%) | N (%) | |||||
| Age (years) | <80 | 29 (93.5) | 520 (91.9) | 0.738 | NA | |
| ≥80 | 2 (6.5) | 46 (8.1) | ||||
| Age subgroups | ≤70 | 19 (5.3) | 337 (94.7) | NA | ||
| 71–75 | 9 (6.5) | 129 (93.5) | ||||
| 76–80 | 2 (2.9) | 68 (97.1) | ||||
| 81–85 | 1 (3.8) | 25 (96.2) | ||||
| ≥86 | 0 (0) | 7 (100) | ||||
| Sex | Female | 3 (9.7) | 212 (37.5) | 0.002 | 1 | 0.022 |
| Male | 28 (90.3) | 354 (62.5) | 4.2 (1.2–14.2) | |||
| BMI | ≥30 kg/m2 | 0 (0) | 18 (3.2) | 0.313 | NA | |
| ASA score | 3,4 | 5 (16.1) | 76 (13.4) | 0.669 | NA | |
| Comorbidity | ||||||
| Diabetes | 6 (19.4) | 106 (18.7) | 0.931 | NA | ||
| Cardiovascular disease | 12 (38.7) | 242 (42.8) | 0.657 | NA | ||
| Pulmonary disease | 5 (16.1) | 57 (10.1) | 0.282 | NA | ||
| Kidney disease | 0 (0) | 7 (1.2) | 0.533 | NA | ||
| Liver disease | 2 (6.5) | 17 (3) | 0.287 | NA | ||
| Cerebrovascular disease | 8 (25.8) | 81 (14.3) | 0.08 | NA | ||
| Emergency | (+) | 1 (4.5) | 23 (5.3) | 0.885 | NA | |
| T4 tumor | (+) | 11 (35.5) | 132 (23.3) | 0.122 | NA | |
| National health insurance | Medical care | 4 (12.9) | 55 (9.7) | 0.563 | NA | |
| Region | Rural (vs. urban) | 10 (32.3) | 157 (27.7) | 0.585 | NA | |
| Preoperative CRT | (+) | 6 (19.4) | 62 (11) | 0.152 | NA | |
| Location | Colon | 5 (16.1) | 319 (56.4) | <0.001 | 1 | 0.001 |
| Rectum | 26 (83.9) | 247 (43.6) | 5.4(2–14.5) | |||
| Surgical approach | Open | 17 (54.8) | 226 (39.9) | 0.1 | NA | |
| Minimally invasive | 14 (45.2) | 340 (60.1) | ||||
| Name of operation | APR, Hartmann | 5 (16.1) | 57 (10.1) | 0.001 | NA | |
| LAR | 22 (71) | 195 (34.5) | ||||
| PC | 0 (0) | 5 (0.9) | ||||
| AR, LHC | 2 (6.5) | 152 (26.9) | ||||
| TC, STC | 0 (0) | 10 (1.8) | ||||
| RHC | 2 (6.5) | 142 (25.1) | ||||
| Other | 0 (0) | 5 (0.9) | ||||
| TNM | II | 14 (45.2) | 221 (39) | 0.497 | NA | |
| III | 17 (54.8) | 345 (61) | ||||
| Metastatic lymph node (number) | 1–3 | 10 (65.2) | 225 (58.8) | 0.590 | NA | |
| ≤4 | 7 (34.8) | 120 (41.2) | ||||
| CRM | ≤1 mm | 5 (19.2) | 45 (18.2) | 0.899 | NA | |
| Histologic grade | G3, G4 | 0 (0) | 51 (9) | 0.081 | NA | |
| 30-day complications | (+) | 18 (58.1) | 152 (26.9) | <0.001 | 2.5 (1.1–5.4) | 0.021 |
| Anastomotic leakage | (+) | 8 (25.8) | 16 (2.8) | <0.001 | NA | |
| Clavien-Dindo grade | 3, 4, 5 | 12 (38.7) | 60 (10.6) | <0.001 | NA | |
| ICU admission | (+) | 8 (25.8) | 140 (24.7) | 0.893 | NA | |
| Transfusion | (+) | 15 (48.4) | 163 (28.8) | 0.02 | 2 (0.9–4.3) | 0.077 |
| Operative time | ≥300 min | 3 (13.6) | 49 (11.2) | 0.723 | NA | |
| Open conversion | (+) | 5 (35.7) | 30 (8.8) | 0.001 | NA | |
BMI, body mass index; ASA, American Society of Anesthesiologists; CRT, chemoradiation; APR, abdominoperineal resection; LAR, low anterior resection; PC, proctocolectomy; AR, anterior resection; LHC, left hemicolectomy; TC, total colectomy; STC, subtotal colectomy; RHC, right hemicolectomy; TNM, tumor-node-metastasis; CRM, circumferential resection margin; ICU, intensive care unit; HR, hazard ratio; CI, confidence interval; NA, not applied